Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OVA-LNP
- Development stage
- Preclinical
- Lead developer
- Cytiva
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Intratumoral
01
Overview
OVA-LNP is a research-grade mRNA vaccine construct consisting of messenger RNA (mRNA) encoding the model antigen ovalbumin (OVA) encapsulated within lipid nanoparticles (LNPs). It is widely utilized in preclinical immuno-oncology research as a surrogate payload to evaluate the efficacy, safety, and immunogenicity of novel LNP delivery platforms and mRNA modification strategies. Studies have demonstrated that unmodified OVA-LNP can induce robust Type I interferon (IFN-I) production and dendritic cell maturation, leading to the expansion of polyfunctional OVA-specific CD8+ T cells and significant anti-tumor activity in B16 melanoma models. The platform is frequently employed by academic institutions, such as the University of Pennsylvania, and biotechnology companies like Cytiva to optimize vaccine formulations and investigate the role of innate immune sensors in the anti-tumor response.
- Other names
- ovalbumin mRNA-LNPOVA mRNA-LNPunmodified OVA-LNPm1Ψ-modified OVA-LNP
02
Targets
APOE (Apolipoprotein E)PRR (Pattern recognition receptors)
Beyond the preview
Go deeper on OVA-LNP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OVA-LNP.